SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantial losses to submit your losses now.
Class Period: Aug. 8, 2023 – Nov. 28, 2023 | |
Lead Plaintiff Deadline: Feb. 9, 2024 | |
Visit: www.hbsslaw.com/investor-fraud/EGRX | |
Contact An Attorney Now: |
EGRX@hbsslaw.com |
844-916-0895 |
Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:
On Jan. 15, 2024, Eagle announced that it had received a limited waiver from its lenders on the defaults and events of default that occurred as a result of the company's (i) impending restatement of Q-2 2023 financials and (ii) failure to timely deliver Q-3 2023 financial statements.
While Eagle's securing the lenders' limited waiver staves off a potential liquidity crisis, Eagle disclosed that until the Company satisfies its financial statement requirements its line of credit has been halved, reducing from $100 million to $50 million.
The line of credit reduction follows ...